Indivior (NASDAQ:INDV) Director David Wheadon Purchases 1,771 Shares

Indivior PLC (NASDAQ:INDV) Director David Wheadon purchased 1,771 shares of Indivior stock in a transaction on Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the acquisition, the director directly owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. This represents a 14.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Indivior Stock Down 1.0%

Shares of INDV traded down $0.35 during mid-day trading on Wednesday, reaching $35.85. 1,097,072 shares of the company’s stock were exchanged, compared to its average volume of 1,460,802. Indivior PLC has a 52-week low of $7.62 and a 52-week high of $38.00. The company has a market cap of $4.48 billion, a price-to-earnings ratio of 39.08 and a beta of 0.75. The company has a 50-day simple moving average of $33.69 and a two-hundred day simple moving average of $25.59.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The firm had revenue of $314.00 million for the quarter, compared to analyst estimates of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. As a group, equities research analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on INDV shares. Morgan Stanley restated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. HC Wainwright lifted their target price on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Craig Hallum reiterated a “buy” rating and issued a $41.00 price target on shares of Indivior in a report on Friday, October 31st. Finally, Northland Securities set a $40.00 price objective on Indivior in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $32.71.

Hedge Funds Weigh In On Indivior

A number of large investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its holdings in shares of Indivior by 544.6% in the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after purchasing an additional 1,013 shares during the last quarter. Goldentree Asset Management LP purchased a new position in shares of Indivior in the 3rd quarter worth $42,630,000. CIBC Bancorp USA Inc. acquired a new position in Indivior in the third quarter valued at $312,000. Jacobs Levy Equity Management Inc. purchased a new stake in Indivior during the third quarter valued at about $33,496,000. Finally, Woodline Partners LP purchased a new stake in Indivior during the third quarter valued at about $6,413,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.